| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/01/2004 | WO2004032862A3 Cyclodextrin-based materials, compositions and uses related thereto |
| 07/01/2004 | WO2004028551A9 Novel agents that modulate eph receptor activity |
| 07/01/2004 | WO2004026111A3 Flexible and/or elastic brachytherapy seed or strand |
| 07/01/2004 | WO2004020014A3 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 07/01/2004 | WO2004016801A3 Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
| 07/01/2004 | WO2004001007A3 Buffered formulations for concentrating antibodies and methods of use thereof |
| 07/01/2004 | WO2003082193A3 Suramin and derivatives thereof as topical microbicide and contraceptive |
| 07/01/2004 | WO2003080569A3 Egfr ligands and methods of use |
| 07/01/2004 | WO2003068942A3 Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses |
| 07/01/2004 | WO2003051278A3 Nanoparticle delivery vehicle |
| 07/01/2004 | WO2002077189A3 Glycosylation-resistant and nonglycosylated cyanovirins |
| 07/01/2004 | US20040127826 Honey in wound dressings |
| 07/01/2004 | US20040127735 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral |
| 07/01/2004 | US20040127696 Growth differentiation factor-7 |
| 07/01/2004 | US20040127686 Signal transduction regulator binding protein for identifying modulators for prevention and treatment of cardiomyopic hypertrophy, heart failure and diabetes; drug screening |
| 07/01/2004 | US20040127684 Heat shock protein-based vaccines and immunotherapies |
| 07/01/2004 | US20040127682 Anti-lymphocyte globulin imunotoxin fusion protein for use in prevention and treatment of graft-versus-host disease, leukemias, lymphomas and autoimmune disorders |
| 07/01/2004 | US20040127578 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics |
| 07/01/2004 | US20040127562 Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| 07/01/2004 | US20040127557 liquid preparations of oxaliplatin, ready to be administered parenterally by infusion; concentration of at least 7 mg/ml; solvent is one hydroxylated derivative chosen from 1,2-propanediol, glycerol, maltitol, sucrose and inositol |
| 07/01/2004 | US20040127541 Bicifadine formulation |
| 07/01/2004 | US20040127537 Stable liquid parenteral parecoxib formulation |
| 07/01/2004 | US20040127490 Administering a therapeutic amount of an alprazolam, estazolam, midazolam or triazolam condensation aerosol for therapy of anxiety or insomnia |
| 07/01/2004 | US20040127481 Administering a therapeutic amount of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride condensation aerosol |
| 07/01/2004 | US20040127466 treatment and prevention of bone diseases in humans, including osteoporosis in postmenopausal women, Paget's Disease and hypercalcemia, by administration of a bisphosphonate in an inhalation form |
| 07/01/2004 | US20040127462 Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae |
| 07/01/2004 | US20040127461 contact lens disinfecting solution; |
| 07/01/2004 | US20040127454 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
| 07/01/2004 | US20040127446 Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
| 07/01/2004 | US20040127425 Control of nitric oxide bioactivity by perfluorocarbons |
| 07/01/2004 | US20040127417 using a poly(ethylene glycol) butyraldehyde moiety; The PEGylated hGH may have an increased plasma residency duration, decreased clearance rate, improved stability, decreased antigenicity, decreased PEGylation heterogeneity or a combination thereof |
| 07/01/2004 | US20040127416 Therapeutic bioconjugates |
| 07/01/2004 | US20040127399 complex consisting of a divalent metal cation associated with and capable of co-precipitating with such a peptide for enhancing the expression of insulin from mammalian pancreatic B-type islet cells |
| 07/01/2004 | US20040127397 covalently attaching the active agent to the N-terminus, the C-terminus or directly to the amino acid side chain of an oligopeptide or polypeptide such that endogeous intestinal peptidases will release said agent |
| 07/01/2004 | US20040127389 Effervescent solid composition of matter |
| 07/01/2004 | US20040126900 Water-soluble polymeric nanoparticle functionalized by at least two peptide moieties with high affinity to therapeutic and cell surface proteins |
| 07/01/2004 | US20040126862 Comprises nucleotide sequences coding protein of urogenital system for identifying moduators for treatment of cell proliferative and metastatic disorders |
| 07/01/2004 | US20040126758 homologous to the known fibrinogen derived haptotactic peptides; shown to elicit activity from fibroblasts, endothelial and smooth muscle cells; for wound healing and enhancing osteogenesis/angiogenesis in vivo with/without medical implant |
| 07/01/2004 | US20040126444 Cactaceae-based formulation having the property of fixing fats and method for obtaining same |
| 07/01/2004 | US20040126423 Pharmaceutical formulation |
| 07/01/2004 | US20040126420 phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, and cholesterol; for removal of extra-/intra- vascular fibrin clots/adhesions; for use during surgery; for treatment of otitis |
| 07/01/2004 | US20040126418 7-alpha-methyl-19-nortestosterone (MENT); androgens; improved bioavailability |
| 07/01/2004 | US20040126410 Method for preparing zinc-oligopeptide easily absorbable by the human body |
| 07/01/2004 | US20040126408 Bioerodible film for ophthalmic drug delivery |
| 07/01/2004 | US20040126403 Treatment for ectoparasites |
| 07/01/2004 | US20040126400 Delivery of therapeutic compounds via microparticles or microbubbles |
| 07/01/2004 | US20040126394 Novel composition |
| 07/01/2004 | US20040126379 Complex containing antibody and cytotoxic compound |
| 07/01/2004 | US20040126376 Binding to monoclonal antibodies; antitumor agents |
| 07/01/2004 | US20040126374 Administering immunoglobulins, insulin protein, epitopes and lymphocyte receptor; prevention, suppression, delay diabetes |
| 07/01/2004 | US20040126367 Oxidation resistance; storage at low temperature; overcoated with liposomes from soybean lecithin |
| 07/01/2004 | US20040126366 Autism, attention deficit , obsessive complusive disorders , mental retardation |
| 07/01/2004 | US20040126361 Polymer conjugates of interferon-beta with enhanced biological potency |
| 07/01/2004 | US20040126360 Oral formulations for proteins and polypeptides |
| 07/01/2004 | US20040126347 hydrofluoroether cosmetic compositions for, make-up, solar protection, perfume, hair removal cream, deodorants, anti-transpiration or shampoo products, and the formulation of pharmaceutical compositions to be applied to the skin |
| 07/01/2004 | US20040126343 a solution, for topical application to a nail of a patient, comprising DMSO a medicine, water and a moisturizing agent for assisting in the retention of moisture in the nail and preventing dehydrating, a dispersant and a solubilizing agent |
| 07/01/2004 | US20040126333 by means of a therapeutic agent delivery device placed within the periodontal pocket, such that release of the therapeutic agents occurs in the immediate vicinity of the disease process, so that biocompatibility or allergic problems cannot arise |
| 07/01/2004 | US20040126330 Nicotine-containing film preparation |
| 07/01/2004 | US20040126329 Delivery of analgesics through an inhalation route |
| 07/01/2004 | US20040126328 Arerosol; heating drug, vaporization, cooling |
| 07/01/2004 | US20040126327 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 07/01/2004 | US20040126326 Delivery of antidepressants through an inhalation route |
| 07/01/2004 | US20040126324 Mixture of ion exchange resin and drug |
| 07/01/2004 | US20040126322 Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
| 07/01/2004 | DE202004006036U1 Base gel, for application as a body lotion to correct acid imbalance through a faulty metabolism, is formulated to be applied three times a week overnight without a need for treatment baths |
| 07/01/2004 | DE10258960A1 Nanoskalige Hydrogele gegen Falten, raue und trockene Haut Nanoscale hydrogels for wrinkles, rough and dry skin |
| 07/01/2004 | CA2810477A1 Oral drug delivery system |
| 07/01/2004 | CA2801155A1 Oral drug delivery system |
| 07/01/2004 | CA2779723A1 Oral drug delivery system |
| 07/01/2004 | CA2510043A1 Tiotropium containing hfc solution formulations |
| 07/01/2004 | CA2510038A1 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base |
| 07/01/2004 | CA2509830A1 Pharmaceutical compositions of sertaconazole for vaginal use |
| 07/01/2004 | CA2509103A1 Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent |
| 07/01/2004 | CA2509101A1 A topical nanoparticulate spironolactone formulation |
| 07/01/2004 | CA2503147A1 Stable topiramate formulations |
| 06/30/2004 | EP1433855A2 Plasmids suitable for il-2 expression |
| 06/30/2004 | EP1433786A1 Benzoxazole compound and pharmaceutical composition containing the compound |
| 06/30/2004 | EP1433482A1 Aqueous preparation containing a shark-derived chondroitin iron sulfate colloid |
| 06/30/2004 | EP1433478A1 Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
| 06/30/2004 | EP1433477A2 External skin treatment stabilized composition comprising retinol |
| 06/30/2004 | EP1432802A2 Pegylated and diglycosylated erythropoietin |
| 06/30/2004 | EP1432738A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| 06/30/2004 | EP1432729A2 Peyers's patch and/or m-cell targeting ligands |
| 06/30/2004 | EP1432725A1 RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432681A1 Pseudopolymorphic forms of carvedilol |
| 06/30/2004 | EP1432527A2 Biological control of nanoparticles |
| 06/30/2004 | EP1432460A2 Bioactive materials for aneurysm repair |
| 06/30/2004 | EP1432457A1 Sanitary napkins with hydrophobic lotions |
| 06/30/2004 | EP1432454A2 Methods for sterilizing preparations containing albumin |
| 06/30/2004 | EP1432449A1 Water-in-oil emulsions comprising vinyl polymers carrying acidic groups in side chains, compositions, and methods |
| 06/30/2004 | EP1432443A2 Angiotensin peptide-carrier conjugates and uses thereof |
| 06/30/2004 | EP1432440A2 Adjuvants for nucleic acid vaccines |
| 06/30/2004 | EP1432437A2 Human tissue urokinase type plasminogen activator formulation |
| 06/30/2004 | EP1432436A2 Nutrient therapy for immuno-compromised patients |
| 06/30/2004 | EP1432431A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 06/30/2004 | EP1432414A1 Use of tazarotene for preparing a nail varnish for treating and/or preventing psoriasis and nail varnish containing same |
| 06/30/2004 | EP1432413A2 3,4-methylenedioxy-substituted chalcones as therapeutic agents |
| 06/30/2004 | EP1432411A1 Timed, sustained release multi-particulate dosage forms of propranolol |
| 06/30/2004 | EP1432410A2 Process for the preparation of fast dissolving effervescent dosage form |